On- and off-label use of rituximab in rheumatic diseases
Steadily growing knowledge about pathogenetic mechanisms in autoimmune rheumatic diseases (RDs) has paved the way to different therapeutic approaches. In particular, the availability of biologics on the market has dramatically modified the natural history of rheumatic chronic inflammatory diseases w...
Main Authors: | Gilda Sandri, Carlo Umberto Manzini, Carlo Salvarani |
---|---|
Format: | Article |
Language: | English |
Published: |
Verduci Editore
2021-04-01
|
Series: | Beyond Rheumatology |
Subjects: | |
Online Access: | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-3-1-56.pdf |
Similar Items
-
Current perspective on rituximab in rheumatic diseases
by: Schioppo T, et al.
Published: (2017-10-01) -
Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases
by: Michaela Fehringer, et al.
Published: (2025-06-01) -
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
by: Mark E. McClure, et al.
Published: (2023-03-01) -
Hypophysitis Secondary to Small Vessel ANCA Vasculitis Treated With Rituximab
by: Nankee K. Kumar, AB, et al.
Published: (2024-03-01) -
Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly
by: Roberta Fenoglio, et al.
Published: (2020-10-01)